Open-House Biologics Discount Contracts 2026-08 - Filgrastim

This tender concerns the conclusion of drug discount contracts for the active substance Filgrastim, under the 'Open-House' procedure as defined by § 130a Abs. 8 of the German Social Code Book V (SGB V). The objective is to secure cost-effective supply of Filgrastim, a medication commonly used to stimulate white blood cell production, for statutory health insurance providers. The 'Open-House' model allows pharmaceutical companies to submit discount offers continuously, enabling statutory health insurance funds to enter into agreements with multiple providers. This procurement mechanism aims to foster competition among manufacturers and distributors, leading to reduced prices for essential medicines. The contracting authority, likely a statutory health insurance fund or a consortium thereof, seeks to leverage this framework to optimize its pharmaceutical spending while ensuring patient access to necessary treatments. The focus on Filgrastim indicates a specific therapeutic area where cost containment is a priority.